KR970706014A - 엠에이치씨-펩티드 복합체의 제조 방법(preparation of mhc-peptide complexes) - Google Patents

엠에이치씨-펩티드 복합체의 제조 방법(preparation of mhc-peptide complexes)

Info

Publication number
KR970706014A
KR970706014A KR1019970702077A KR19970702077A KR970706014A KR 970706014 A KR970706014 A KR 970706014A KR 1019970702077 A KR1019970702077 A KR 1019970702077A KR 19970702077 A KR19970702077 A KR 19970702077A KR 970706014 A KR970706014 A KR 970706014A
Authority
KR
South Korea
Prior art keywords
peptide
mhc
mhc component
molecule
complex
Prior art date
Application number
KR1019970702077A
Other languages
English (en)
Inventor
내그 비시와짓
엘. 윙클헤크 제프리
브이. 무쿠 프라바
Original Assignee
슈리캔트 데슈팬드
애너진, 인코오포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 슈리캔트 데슈팬드, 애너진, 인코오포레이티드 filed Critical 슈리캔트 데슈팬드
Publication of KR970706014A publication Critical patent/KR970706014A/ko

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4713—Autoimmune diseases, e.g. Insulin-dependent diabetes mellitus, multiple sclerosis, rheumathoid arthritis, systemic lupus erythematosus; Autoantigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/36—Extraction; Separation; Purification by a combination of two or more processes of different types
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70539—MHC-molecules, e.g. HLA-molecules
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Rehabilitation Therapy (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Cell Biology (AREA)
  • Transplantation (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Analytical Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

본 발명은 정해진 조성의 MHC-펩티드 복합체의 제조 방법을 제공한다. 본 방법은 매우 몰 과량의 펩티드를 사용한다. 한편, 상기 방법은 최적화된 pH 조건을 사용한다.

Description

엠에이치씨-펩티드 복합체의 제조 방법(PREPARATION OF MHC-PEPTIDE COMPLEXES)
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음

Claims (16)

  1. 항원성 펩티드와 MHC 성분을 포함하는 복합체의 제조 방법으로서, MHC 성분을 약 75배 내지 약2000배몰 과량의 펩티드와 접촉기켜 MHC Ⅱ류-펩티드 복합체를 형성하는 단계를 포함하는 방법.
  2. 제1항에 있어서, MHC 성분이 HLA-DR2 분자인 방법.
  3. 제2항에 있어서, MHC 성분이 DRB*1501 분자를 포함하는 방법.
  4. 제2항에 있어서, MHC 성분이 DRB*0101 분자를 포함하는 방법.
  5. 제1항에 있어서, 항원성 펩티드가 미엘린 염기성 단백질에서 유래한 것인 방법.
  6. 제1항에 있어서, 항원성 펩티드가 MBP(83-102)Y83인 방법.
  7. 제1항에 있어서, 약 100배 내지 약300배 몰 과량의 펩티드를 사용하여 접촉 단계를 수행하는 방법.
  8. 제1항에 있어서, MHC Ⅱ류-펩티드 복합체를 치료 또는 진단용으로 투여하기에 적합한 비율로 약학적으로 허용가능한 부형제와 혼합하는 단계를 추가로 포함하는 방법.
  9. 항원성 펩티드와 MHC 성분을 포함하는 복합체의 제조 방밥으로서, MHC 성분을 최적 pH 조건하에 상기 펩티드와 접촉시켜 MHC Ⅱ류-펩티드 복합제를 형성하는 단계를 포함하는 방법.
  10. 제9항에 있어서, MHC 성분이 DR2인 방법.
  11. 제10항에 있어서, MHC 성분이 DRB*1501 분자를 포함하는 방법.
  12. 제10항에 있어서, MHC 성분이 DRB*0101 분자를 포함하는 방법.
  13. 제10항에 있어서, 펩티드가 MBP(83-102)Y83이고, 최적 pH 조건이 약 pH 6인 방법.
  14. 제10항에 있어서, 펩티드가 MBP(124-143)이고, 최적 pH 조건이 약 pH 8인 방법.
  15. 제10항에 있어서, 펩티드가 MBP(143-168)이고, 최적 pH 조건이 약 pH 7인 방법.
  16. 제9항에 있어서, MHC Ⅱ류-펩티드 복합체를 치료 또는 진단용으로 투여하기에 적합한 비율로 약학적허용 부형제와 혼합하는 단계를 추가로 포함하는 방법.
    ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019970702077A 1994-09-30 1995-09-29 엠에이치씨-펩티드 복합체의 제조 방법(preparation of mhc-peptide complexes) KR970706014A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US31553994A 1994-09-30 1994-09-30
US08/315,539 1994-09-30
PCT/US1995/012575 WO1996010415A1 (en) 1994-09-30 1995-09-29 Preparation of mhc-peptide complexes

Publications (1)

Publication Number Publication Date
KR970706014A true KR970706014A (ko) 1997-11-03

Family

ID=23224886

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019970702077A KR970706014A (ko) 1994-09-30 1995-09-29 엠에이치씨-펩티드 복합체의 제조 방법(preparation of mhc-peptide complexes)

Country Status (6)

Country Link
EP (1) EP0792157A4 (ko)
JP (1) JPH10509693A (ko)
KR (1) KR970706014A (ko)
AU (1) AU3887495A (ko)
CA (1) CA2201519A1 (ko)
WO (1) WO1996010415A1 (ko)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5824315A (en) * 1993-10-25 1998-10-20 Anergen, Inc. Binding affinity of antigenic peptides for MHC molecules
EP0792157A4 (en) * 1994-09-30 1999-12-01 Anergen Inc PREPARATIONS OF PEPTIDE COMPLEXES / MAJOR HISTOCOMPATIBILITY SYSTEM
WO2002081683A2 (en) * 2001-04-05 2002-10-17 Nextgen Sciences Ltd. Protein analysis by means of immobilized arrays of antigens or antibodies

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5468481A (en) * 1988-06-23 1995-11-21 Amergen, Inc. MHC class II-peptide conjugates useful in ameliorating autoimmunity
US5130297A (en) * 1988-06-23 1992-07-14 Anergen, Inc. Conjugates useful in ameliorating autoimmunity MHC-II-peptide
US5260422A (en) * 1988-06-23 1993-11-09 Anergen, Inc. MHC conjugates useful in ameliorating autoimmunity
US5194425A (en) * 1988-06-23 1993-03-16 Anergen, Inc. Mhc-mediated toxic conjugates useful in ameliorating autoimmunity
JP3926839B2 (ja) * 1993-09-14 2007-06-06 エピミューン，インコーポレイティド 万能ｄｒ−結合性ペプチドを用いる免疫応答の改変
EP0792157A4 (en) * 1994-09-30 1999-12-01 Anergen Inc PREPARATIONS OF PEPTIDE COMPLEXES / MAJOR HISTOCOMPATIBILITY SYSTEM

Also Published As

Publication number Publication date
EP0792157A4 (en) 1999-12-01
AU3887495A (en) 1996-04-26
EP0792157A1 (en) 1997-09-03
JPH10509693A (ja) 1998-09-22
CA2201519A1 (en) 1996-04-11
WO1996010415A1 (en) 1996-04-11

Similar Documents

Publication Publication Date Title
WO1990006696A3 (en) Meningococcal class 1 outer-membrane protein vaccine
PL345923A1 (en) Cosmetic and pharmaceutic emulsions of oil-in-water type
BR0005936A (pt) Liberação de produtos farmacêuticos instáveis
DK16487A (da) Vacciner til oral indgift
ID28003A (id) Turunan-turunan adamantana
PL399138A1 (pl) Peptyd tolerogenny, kompozycja farmaceutyczna zawierająca ten peptyd, peptyd lub kompozycja farmaceutyczna do podawania i zastosowanie peptydu tolerogennego
WO2000012542A3 (en) Cytotoxic lactoferrin derivatives modified by bulky or lipophilic moieties
RS49907B (sr) Koncentrat delotvorne supstance sa formoterolom koji je duže upotrebljiv
HUP0202537A2 (hu) Vakcinakészítmény és eljárás annak alkalmazására
CA2246715A1 (en) Antibody variants
KR960000247A (ko) 사이클로스포린a 함유 조성물 및 그의 제조방법
BR9914631A (pt) Composição imunológica oral indutora de tolerância para prevenção e/ou tratamento de enfermidades e método para prevenção e/ou tratamento de enfermidades
GB2302505A (en) Stabilisation of photosensitive materials
NO972219D0 (no) Immunogenpreparater
FI925649A0 (fi) Karboxivinylpolymerer med newtonsk viskositet
KR970706014A (ko) 엠에이치씨-펩티드 복합체의 제조 방법(preparation of mhc-peptide complexes)
CA2236641A1 (en) Preparation of fagopyritols and uses therefor
DE69530380D1 (de) Retropeptide, antikörper dagegen und deren verwendungen in der impfung und in vitro diagnostik
NO993407L (no) Fremstilling av proteinpreparater med nedsatt aggregatinnhold
EP0955366A4 (en) ANTIGENIC PROTEIN FROM MALASSEZIA
KR880003621A (ko) 의약 제제물
KR910700259A (ko) T-세포 인지성 펩티드 변형에 의해 면역반응에 영향을 주는 방법
HUP0004362A2 (hu) Karbamazepint vagy származékait tartalmazó parenterális készítmények
WO1999012945A3 (en) Hydrophobic glycosylamine derivatives, compositions, and methods for use
EE03146B1 (et) Bioaktiivseid steroide sisaldavad farmatseutilised emulsioonid, nende valmistamismeetod ja kasutamine

Legal Events

Date Code Title Description
A201 Request for examination
E902 Notification of reason for refusal
E701 Decision to grant or registration of patent right
NORF Unpaid initial registration fee